## Hitinder S Gurm

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3183405/publications.pdf

Version: 2024-02-01

34016 33814 11,294 231 52 citations h-index papers

g-index 233 233 233 11031 docs citations times ranked citing authors all docs

99

#	Article	IF	CITATIONS
1	Profile and prevalence of aspirin resistance in patients with cardiovascular disease. American Journal of Cardiology, 2001, 88, 230-235.	0.7	760
2	Long-Term Results of Carotid Stenting versus Endarterectomy in High-Risk Patients. New England Journal of Medicine, 2008, 358, 1572-1579.	13.9	732
3	Association Between Admission Neutrophil to Lymphocyte Ratio and Outcomes in Patients With Acute Coronary Syndrome. American Journal of Cardiology, 2008, 102, 653-657.	0.7	706
4	Door-to-Balloon Time and Mortality among Patients Undergoing Primary PCI. New England Journal of Medicine, 2013, 369, 901-909.	13.9	609
5	Usefulness of an Elevated Neutrophil to Lymphocyte Ratio in Predicting Long-Term Mortality After Percutaneous Coronary Intervention. American Journal of Cardiology, 2006, 97, 993-996.	0.7	353
6	Renal Function-Based Contrast Dosing to Define Safe Limits of Radiographic Contrast Media in Patients Undergoing Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2011, 58, 907-914.	1.2	271
7	How A Regional Collaborative Of Hospitals And Physicians In Michigan Cut Costs And Improved The Quality Of Care. Health Affairs, 2011, 30, 636-645.	2.5	258
8	Noninvasive Thrombolysis Using Pulsed Ultrasound Cavitation Therapy – Histotripsy. Ultrasound in Medicine and Biology, 2009, 35, 1982-1994.	0.7	203
9	The impact of body mass index onshort- and long-term outcomes inpatients undergoing coronary revascularization. Journal of the American College of Cardiology, 2002, 39, 834-840.	1.2	199
10	A Novel Tool for Reliable and Accurate Prediction of Renal Complications in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2013, 61, 2242-2248.	1.2	183
11	The Relative Renal Safety of Iodixanol Compared With Low-Osmolar Contrast Media. JACC: Cardiovascular Interventions, 2009, 2, 645-654.	1.1	181
12	Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. American Journal of Cardiology, 2004, 93, 1176-1178.	0.7	174
13	Impact of body mass index on outcome after percutaneous coronary intervention (the obesity) Tj ETQq1 1 0.7843	314 rgBT / 0.7	Overlock 10
14	Operator Experience and Carotid Stenting Outcomes in Medicare Beneficiaries. JAMA - Journal of the American Medical Association, 2011, 306, 1338.	3.8	158
15	Renal failure after percutaneous coronary intervention is associated with high mortality. Catheterization and Cardiovascular Interventions, 2005, 64, 442-448.	0.7	143
16	Failure of Guideline Adherence for Intervention in Patients With Severe Mitral Regurgitation. Journal of the American College of Cardiology, 2009, 54, 860-865.	1,2	143
17	Noninvasive Treatment of Deep Venous Thrombosis Using Pulsed Ultrasound Cavitation Therapy (Histotripsy) in a Porcine Model. Journal of Vascular and Interventional Radiology, 2011, 22, 369-377.	0.2	142
18	Trends in Door-to-Balloon Time and Mortality in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Archives of Internal Medicine, 2010, 170, 1842-9.	4.3	130

#	Article	IF	Citations
19	Gaps in Referral to Cardiac Rehabilitation of Patients Undergoing Percutaneous Coronary Intervention in the United States. Journal of the American College of Cardiology, 2015, 65, 2079-2088.	1.2	130
20	Does Simplicity Compromise Accuracy in ACS Risk Prediction? A Retrospective Analysis of the TIMI and GRACE Risk Scores. PLoS ONE, 2009, 4, e7947.	1.1	123
21	Short term and intermediate term comparison of endarterectomy versus stenting for carotid artery stenosis: systematic review and meta-analysis of randomised controlled clinical trials. BMJ: British Medical Journal, 2010, 340, c467-c467.	2.4	122
22	Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Medicine, 2009, 7, 23.	2.3	120
23	Current role of sodium bicarbonate–based preprocedural hydration for the prevention of contrast-induced acute kidney injury: A meta-analysis. American Heart Journal, 2008, 156, 414-421.	1.2	107
24	Outcomes of PCI in Relation to ProceduralÂCharacteristics and OperatorÂVolumes inÂthe United States. Journal of the American College of Cardiology, 2017, 69, 2913-2924.	1.2	104
25	Use of Mechanical Circulatory Support in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2015, 132, 1243-1251.	1.6	100
26	Gender differences in adverse outcomes after contemporary percutaneous coronary intervention: An analysis from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) percutaneous coronary intervention registry. American Heart Journal, 2010, 159, 677-683.e1.	1.2	98
27	The association of sex with outcomes among patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction in the contemporary era: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). American Heart Journal, 2011, 161, 106-112.e1.	1.2	97
28	Changes in Primary Noncardiac Diagnoses Over Time Among Elderly Cardiac Intensive Care Unit Patients in the United States. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, e003616.	0.9	96
29	The Relative Safety and Efficacy of Abciximab and Eptifibatide in Patients Undergoing Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2008, 51, 529-535.	1.2	94
30	Procedural Strategies to Reduce theÂlncidence of Contrast-Induced AcuteÂKidney Injury During PercutaneousÂCoronary Intervention. JACC: Cardiovascular Interventions, 2019, 12, 1877-1888.	1.1	91
31	Bivalirudin versus heparin and glycoprotein Ilb/Illa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). American Journal of Cardiology, 2005, 95, 581-585.	0.7	89
32	Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials. European Heart Journal, 2008, 30, 44-55.	1.0	88
33	The association of perioperative transfusion with 30-day morbidity and mortality in patients undergoing major vascular surgery. Journal of Vascular Surgery, 2015, 61, 1000-1009.e1.	0.6	83
34	The changing definition of contrast-induced nephropathy and its clinical implications: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). American Heart Journal, 2012, 163, 829-834.	1,2	78
35	Retroperitoneal Hematoma After Percutaneous Coronary Intervention: Prevalence, Risk Factors, Management, Outcomes, and Predictors of Mortality. JACC: Cardiovascular Interventions, 2010, 3, 845-850.	1.1	76
36	Impact of Sex on Morbidity and Mortality Rates After Lower Extremity Interventions for Peripheral Arterial Disease. Journal of the American College of Cardiology, 2014, 63, 2525-2530.	1,2	75

#	Article	IF	CITATIONS
37	Current Approach to the Diagnosis and Treatment of Femoral-Popliteal Arterial Disease. A Systematic Review. Current Cardiology Reviews, 2009, 5, 296-311.	0.6	74
38	Risk of Acute Kidney Injury After Percutaneous Coronary Interventions Using Radial Versus Femoral Vascular Access. Circulation: Cardiovascular Interventions, 2014, 7, 190-198.	1.4	74
39	Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. American Journal of Cardiology, 2005, 95, 490-491.	0.7	72
40	Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial. Lancet, The, 2018, 391, 1997-2007.	6.3	70
41	Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease. Circulation, 2007, 115, 2398-2409.	1.6	68
42	Safety and efficacy of thrombectomy in patients undergoing primary percutaneous coronary intervention for Acute ST elevation MI: A Meta-Analysis of Randomized Controlled Trials. BMC Cardiovascular Disorders, 2010, 10, 10.	0.7	67
43	Trends and disparities in referral to cardiac rehabilitation after percutaneous coronary intervention. American Heart Journal, 2011, 161, 544-551.e2.	1.2	67
44	Outcomes of Patients With AtrialÂFibrillation Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2016, 68, 895-904.	1.2	65
45	Chronic Obstructive Pulmonary Disease as a Predictor of Mortality in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2005, 96, 756-759.	0.7	61
46	A Comparison of Abciximab and Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2009, 2, 230-236.	1.4	61
47	Impact of Blood Transfusion on Short- and Long-Term Mortality in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2009, 2, 46-53.	1.1	61
48	Safety of carotid artery stenting for symptomatic carotid artery disease: a meta-analysis. European Heart Journal, 2007, 29, 113-119.	1.0	59
49	Association Between Acute Kidney Injury and In-Hospital Mortality in Patients Undergoing Percutaneous Coronary Interventions. Circulation: Cardiovascular Interventions, 2015, 8, e002212.	1.4	57
50	Meta-Analysis of Randomized Trials of Drug-Eluting Stents Versus Bare Metal Stents in Patients With Diabetes Mellitus. American Journal of Cardiology, 2007, 99, 1399-1402.	0.7	56
51	Preprocedural white blood cell count and death after percutaneous coronary intervention. American Heart Journal, 2003, 146, 692-698.	1.2	53
52	Noninvasive thrombolysis using histotripsy beyond the intrinsic threshold (microtripsy). IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2015, 62, 1342-1355.	1.7	53
53	Variation in the Adoption of TransradialÂAccess for ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2017, 10, 2242-2254.	1.1	53
54	Sildenafil Citrate for Prophylaxis of Nephropathy in an Animal Model of Contrast-Induced Acute Kidney Injury. PLoS ONE, 2014, 9, e113598.	1.1	53

#	Article	IF	CITATIONS
55	Spectrum of atrial arrhythmias using the ligament of Marshall in patients with atrial fibrillation. Heart Rhythm, 2018, 15, 17-24.	0.3	52
56	In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2014, 7, 585-593.	1,4	49
57	Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan) Tj ETQq $1\ 1$	0.784314	rgBT/Overlo
58	Histotripsy Thrombolysis on Retracted Clots. Ultrasound in Medicine and Biology, 2016, 42, 1903-1918.	0.7	49
59	Change in Hospital-Level Use of Transradial Percutaneous Coronary Intervention and Periprocedural Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 550-559.	0.9	47
60	Percutaneous Coronary Intervention Complications and Guide Catheter Size. JACC: Cardiovascular Interventions, 2009, 2, 636-644.	1.1	46
61	Recent Trends in Hospital Utilization for Acute Myocardial Infarction and Coronary Revascularization in the United States. American Journal of Cardiology, 2007, 99, 749-753.	0.7	45
62	Non-Invasive Thrombolysis Using Microtripsy in a Porcine Deep Vein Thrombosis Model. Ultrasound in Medicine and Biology, 2017, 43, 1378-1390.	0.7	45
63	Drug-Eluting versus Bare-Metal Stent for Treatment of Saphenous Vein Grafts: A Meta-Analysis. PLoS ONE, 2010, 5, e11040.	1.1	45
64	The Quality and Impact of Risk Factor Control in Patients With Stable Claudication Presenting for Peripheral Vascular Interventions. Circulation: Cardiovascular Interventions, 2012, 5, 850-855.	1.4	44
65	The Burgeoning Epidemic of Morbid Obesity in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2013, 62, 685-691.	1.2	43
66	Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention. Circulation, 2019, 139, 458-472.	1.6	43
67	Coronary artery perforations after contemporary percutaneous coronary interventions: Evaluation of incidence, risk factors, outcomes, and predictors of mortality. Catheterization and Cardiovascular Interventions, 2017, 89, 966-973.	0.7	42
68	Contrastâ€induced nephropathy in patients undergoing endovascular peripheral vascular intervention: Incidence, risk factors, and outcomes as observed in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Journal of Interventional Cardiology, 2017, 30, 274-280.	0.5	42
69	Daylight savings time and myocardial infarction. Open Heart, 2014, 1, e000019.	0.9	41
70	Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, e003070.	1.4	41
71	Thrombin, an ideal target for pharmacological inhibition: A review of direct thrombin inhibitors. American Heart Journal, 2005, 149, S43-S53.	1.2	40
72	Use of Bivalirudin During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. Journal of the American College of Cardiology, 2005, 45, 1932-1938.	1.2	40

#	Article	IF	Citations
73	Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2015, 65, 2714-2723.	1.2	40
74	Temporal Trends in Percutaneous CoronaryÂlntervention and Coronary Artery Bypass Grafting: Insights From the Washington Cardiac Care Outcomes Assessment Program. Journal of the American Heart Association, 2020, 9, e015317.	1.6	40
75	Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. American Journal of Cardiology, 2004, 94, 30-34.	0.7	39
76	Contemporary Use and Effectiveness of N-Acetylcysteine in Preventing Contrast-Induced Nephropathy Among Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 98-104.	1.1	38
77	Contemporary use of and outcomes associated with ultra″ow contrast volume in patients undergoing percutaneous coronary interventions. Catheterization and Cardiovascular Interventions, 2019, 93, 222-230.	0.7	38
78	Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting. American Heart Journal, 2000, 139, 939-944.	1.2	36
79	Defining the Optimal Degree of Heparin Anticoagulation for Peripheral Vascular Interventions. Circulation: Cardiovascular Interventions, 2010, 3, 593-601.	1.4	36
80	Comparison of Acute Coronary Syndrome in Patients Receiving Versus Not Receiving Chronic Dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry). American Journal of Cardiology, 2012, 109, 19-25.	0.7	36
81	Early Outcomes following Endovascular, Open Surgical, and Hybrid Revascularization for Lower Extremity Acute Limb Ischemia. Annals of Vascular Surgery, 2018, 51, 106-112.	0.4	36
82	Fragmented QRS Complex Has Poor Sensitivity in Detecting Myocardial Scar. Annals of Noninvasive Electrocardiology, 2010, 15, 308-314.	0.5	34
83	ACC/AHA/SCAI/AMA–Convened PCPI/NCQA 2013 Performance Measures for Adults Undergoing Percutaneous Coronary Intervention. Circulation, 2014, 129, 926-949.	1.6	34
84	The Ongoing Importance of Smoking as a Powerful Risk Factor for ST-Segment Elevation Myocardial Infarction in Young Patients. JAMA Internal Medicine, 2013, 173, 1261.	2.6	33
85	Contemporary Use of Prasugrel in Clinical Practice. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 293-298.	0.9	33
86	Contemporary outcomes with percutaneous vascular interventions for peripheral critical limb ischemia in those with and without poly-vascular disease. Vascular Medicine, 2014, 19, 491-499.	0.8	33
87	Percutaneous Coronary Intervention for Chronic Total Occlusion—The Michigan Experience. JACC: Cardiovascular Interventions, 2020, 13, 1357-1368.	1.1	33
88	Patient and Hospital Characteristics Associated With Inappropriate Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2013, 62, 2274-2281.	1.2	32
89	The Association between Contrast Dose and Renal Complications Post PCI across the Continuum of Procedural Estimated Risk. PLoS ONE, 2014, 9, e90233.	1.1	31
90	Effect of a Contrast Modulation SystemÂon Contrast Media Use and the Rate ofÂAcute Kidney Injury After Coronary Angiography. JACC: Cardiovascular Interventions, 2018, 11, 1601-1610.	1.1	31

#	Article	IF	CITATIONS
91	A Random Forest Based Risk Model for Reliable and Accurate Prediction of Receipt of Transfusion in Patients Undergoing Percutaneous Coronary Intervention. PLoS ONE, 2014, 9, e96385.	1.1	31
92	Long-Term Outcomes of Older Diabetic Patients After Percutaneous Coronary Stenting in the United States. Journal of the American College of Cardiology, 2012, 60, 2280-2289.	1.2	30
93	Noninvasive thrombolysis using microtripsy: a parameter study. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2015, 62, 2092-2105.	1.7	30
94	Heterogeneity of Ankle-Brachial Indices inÂPatients Undergoing Revascularization forÂCriticalÂLimb Ischemia. JACC: Cardiovascular Interventions, 2017, 10, 2307-2316.	1.1	29
95	Comparative Safety of Vascular Closure Devices and Manual Closure Among Patients Having Percutaneous Coronary Intervention. Annals of Internal Medicine, 2013, 159, 660.	2.0	29
96	Effect of chronic kidney disease on outcomes after carotid artery stenting. American Journal of Cardiology, 2004, 94, 1093-1096.	0.7	28
97	Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. American Heart Journal, 2006, 152, 149-154.	1.2	28
98	Outcome of Contemporary Percutaneous Coronary Intervention in the Elderly and the Very Elderly: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Clinical Cardiology, 2011, 34, 549-554.	0.7	28
99	Impact of Automated Contrast Injector Systems on Contrast Use and Contrast-Associated Complications in Patients Undergoing Percutaneous Coronary Interventions. JACC: Cardiovascular Interventions, 2013, 6, 399-405.	1.1	28
100	ACC/AHA/SCAI/AMA–Convened PCPI/NCQA 2013 Performance Measures for Adults Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2014, 63, 722-745.	1.2	28
101	Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, e003464.	1.4	28
102	Minimizing radiographic contrast administration during coronary angiography using a novel contrast reduction system: A multicenter observational study of the DyeVertâ,,¢ plus contrast reduction system. Catheterization and Cardiovascular Interventions, 2019, 93, 1228-1235.	0.7	28
103	Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein llb/llla inhibition. Journal of the American College of Cardiology, 2004, 43, 542-548.	1.2	26
104	The association between patient race, treatment, and outcomes of patients undergoing contemporary percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). American Heart Journal, 2013, 165, 893-901.e2.	1.2	26
105	Real-Time Feedback of Histotripsy Thrombolysis Using Bubble-Induced Color Doppler. Ultrasound in Medicine and Biology, 2015, 41, 1386-1401.	0.7	26
106	The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice. Expert Opinion on Drug Safety, 2008, 7, 809-819.	1.0	25
107	The comparative efficacy of bivalirudin is markedly attenuated by use of radial access: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium. European Heart Journal, 2016, 37, 1902-1909.	1.0	24
108	Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. American Journal of Cardiology, 2004, 94, 190-192.	0.7	23

#	Article	IF	CITATIONS
109	Safety of Contemporary Percutaneous Peripheral Arterial Interventions in the Elderly. JACC: Cardiovascular Interventions, 2011, 4, 694-701.	1.1	23
110	Cause and Circumstance of In-Hospital Mortality Among Patients Undergoing Contemporary Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 229-235.	0.9	22
111	Association Between Chronic Kidney Disease and Rates of Transfusion and Progression to Endâ€5tage Renal Disease in Patients Undergoing Transradial Versus Transfemoral Cardiac Catheterization—An Analysis From the Veterans Affairs Clinical Assessment Reporting and Tracking (CART) Program. Journal of the American Heart Association. 2017. 6	1.6	22
112	Primary and Secondary Vascular Access Site Complications Associated With Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2019, 12, 2247-2256.	1.1	22
113	Collaborative quality improvement vs public reporting for percutaneous coronary intervention: A comparison of percutaneous coronary intervention in New York vs Michigan. American Heart Journal, 2015, 170, 1227-1233.	1.2	21
114	Trends in Contrast Volume Use and Incidence of AcuteÂKidney Injury in Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 509-511.	1.1	21
115	Relationship Between Troponin on Presentation and Inâ€Hospital Mortality in Patients With STâ€Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Journal of the American Heart Association, 2019, 8, e013551.	1.6	21
116	Comparative safety and efficacy of a sirolimus-eluting versus paclitaxel-eluting stent: A meta-analysis. American Heart Journal, 2008, 155, 630-639.	1.2	20
117	Association of Operator and Hospital Experience With Procedural Success Rates and Outcomes in Patients Undergoing Percutaneous Coronary Interventions for Chronic Total Occlusions. Circulation: Cardiovascular Interventions, 2020, 13, e008863.	1.4	20
118	Does gadoliniumâ€based angiography protect against contrastâ€induced nephropathy?: A systematic review of the literature. Catheterization and Cardiovascular Interventions, 2008, 71, 687-693.	0.7	19
119	Temporal Trends in the Use of Drugâ€eluting Stents for Approved and Offâ€label Indications: A Longitudinal Analysis of a Large Multicenter Percutaneous Coronary Intervention Registry. Clinical Cardiology, 2010, 33, 111-116.	0.7	19
120	Cardiac Rehabilitation Use After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2019, 73, 3148-3152.	1.2	19
121	Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. American Journal of Cardiology, 2005, 95, 716-721.	0.7	18
122	Drivers of Variation in 90-Day Episode Payments After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e006928.	1.4	18
123	Looking Beyond Historical Patient Outcomes to Improve Clinical Models. Science Translational Medicine, 2012, 4, 131ra49.	5.8	17
124	A pulsatile blood vessel system for a femoral arterial access clinical simulation model. Medical Engineering and Physics, 2013, 35, 1518-1524.	0.8	17
125	The Clinical Impact of Cardiology Consultation Prior to Major Vascular Surgery. Annals of Surgery, 2018, 267, 189-195.	2.1	17
126	Temporal Trends in Unstable Angina Diagnosis Codes for Outpatient Percutaneous Coronary Interventions. JAMA Internal Medicine, 2019, 179, 259.	2.6	17

#	Article	IF	CITATIONS
127	Integrated Histotripsy and Bubble Coalescence Transducer for Thrombolysis. Ultrasound in Medicine and Biology, 2018, 44, 2697-2709.	0.7	16
128	Determinants of Hospital Variation in Cardiac Rehabilitation Enrollment During Coronary Artery Disease Episodes of Care. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007144.	0.9	16
129	False activation of the cardiac catheterization laboratory for primary PCI. American Journal of Managed Care, 2013, 19, 671-5.	0.8	16
130	Non-Invasive Embolus Trap Using Histotripsyâ€"An Acoustic Parameter Study. Ultrasound in Medicine and Biology, 2013, 39, 611-619.	0.7	15
131	The Clinical Outcomes of Percutaneous Coronary Intervention Performed Without Pre-Procedural Aspirin. Journal of the American College of Cardiology, 2013, 62, 2083-2089.	1.2	15
132	Door to Balloon Time: Is There a Point That Is Too Short?. Progress in Cardiovascular Diseases, 2015, 58, 230-240.	1.6	15
133	Underutilization of Radial Access in Patients Undergoing Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	15
134	Using simulation for teaching femoral arterial access: A multicentric collaboration. Catheterization and Cardiovascular Interventions, 2016, 87, 376-380.	0.7	15
135	The Heart Protection Study: high-risk patients benefit from statins, regardless of LDL-C level Cleveland Clinic Journal of Medicine, 2003, 70, 991-997.	0.6	15
136	Impact of Body Mass Index on Outcome in Patients Undergoing Carotid Stenting. American Journal of Cardiology, 2005, 96, 1743-1745.	0.7	14
137	Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (≥65 Years) Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue Cross Blue) Tj ETQq1 1 0.	784 <b>3)17</b> 4 rgBT	Dwerlock
138	If not now, when? Prescription of evidence-based medical therapy prior to hospital discharge increases utilization at 6 months in patients with symptomatic peripheral artery disease. Vascular Medicine, 2015, 20, 544-550.	0.8	13
139	Temporal trends in peripheral arterial interventions: Observations from the blue cross blue shield of Michigan cardiovascular consortium (BMC2 PVI). Catheterization and Cardiovascular Interventions, 2017, 89, 728-734.	0.7	13
140	Computational Fluid Dynamics Modeling of the Burr Orbital Motion in Rotational Atherectomy with Particle Image Velocimetry Validation. Annals of Biomedical Engineering, 2018, 46, 567-578.	1.3	13
141	Percutaneous Coronary Intervention Utilization and Appropriateness across the United States. PLoS ONE, 2015, 10, e0138251.	1,1	13
142	Is Simpler Also Better? Brief Sodium Bicarbonate Infusion to Prevent Contrast-Induced Nephropathy. American Journal of Cardiology, 2010, 105, 1042-1043.	0.7	12
143	Differences in the outcome of patients undergoing percutaneous coronary interventions at teaching versus non-teaching hospitals. American Heart Journal, 2013, 166, 401-408.	1.2	12
144	Outcomes After Percutaneous Coronary Intervention in Patients With a History of Cerebrovascular Disease. Circulation: Cardiovascular Interventions, 2018, 11, e006400.	1.4	12

#	Article	IF	CITATIONS
145	The relative renal safety of iodixanol and low-osmolar contrast media in patients undergoing percutaneous coronary intervention. Insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Journal of Invasive Cardiology, 2010, 22, 467-72.	0.4	12
146	Impact of Contrast Dose Reduction on Incidence of Acute Kidney Injury (AKI) Among Patients Undergoing PCI: A Modeling Study. Journal of Invasive Cardiology, 2016, 28, 142-6.	0.4	12
147	Impact of diabetes mellitus on outcome of patients undergoing carotid artery stenting: Insights from a single center registry. Catheterization and Cardiovascular Interventions, 2007, 69, 541-545.	0.7	11
148	Comparative Effectiveness and Safety of a Catheterization Laboratory–Only Eptifibatide Dosing Strategy in Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, e001880.	1.4	11
149	Hemodynamic and Hematologic Effects of Histotripsy of Free-Flowing Blood: Implications for Ultrasound-Mediated Thrombolysis. Journal of Vascular and Interventional Radiology, 2015, 26, 1559-1565.	0.2	11
150	Tailored Versus Standard Hydration to Prevent Acute Kidney Injury After Percutaneous Coronary Intervention: Network Metaâ€Analysis. Journal of the American Heart Association, 2021, 10, e021342.	1.6	11
151	Cardiogenic Shock Complicating Myocardial Infarction. Critical Care Clinics, 2007, 23, 759-777.	1.0	10
152	Temporal Trends, Safety, and Efficacy of Bivalirudin in Elective Percutaneous Coronary Intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Journal of Interventional Cardiology, 2007, 20, 197-203.	0.5	10
153	Appropriateness and Outcomes of Percutaneous Coronary Intervention at Top-Ranked and Nonranked Hospitals in Athe United States. JACC: Cardiovascular Interventions, 2018, 11, 342-350.	1.1	10
154	Eroding the Denominator. Journal of the American College of Cardiology, 2012, 60, 789-790.	1.2	9
155	Radial PCI and the obesity paradox: Insights from blue cross blue shield of michigan cardiovascular consortium (BMC2). Catheterization and Cardiovascular Interventions, 2016, 87, 211-219.	0.7	9
156	Impact of institutional culture on rates of transfusions during cardiovascular procedures: The Michigan experience. American Heart Journal, 2016, 174, 1-6.	1.2	9
157	Trends in Utilization, and Comparative Safety and Effectiveness of Orbital and Rotational Atherectomy. JACC: Cardiovascular Interventions, 2020, 13, 146-148.	1.1	9
158	Institutional Variability in Patient Radiation DosesÂ≥5ÂGy During Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2020, 13, 846-856.	1.1	9
159	In-vivo study of non-invasive thrombolysis by histotripsy in a porcine model. , 2009, , .		8
160	Current medical management of stable coronary artery disease before and after elective percutaneous coronary intervention. American Heart Journal, 2013, 165, 778-784.	1.2	8
161	The Epidemiology and Outcomes of Percutaneous Coronary Intervention Before Highâ€Risk Noncardiac Surgery in Contemporary Practice: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) Registry. Journal of the American Heart Association, 2014, 3, e000388.	1.6	8
162	The optimal definition of contrast-induced acute kidney injury for prediction of inpatient mortality in patients undergoing percutaneous coronary interventions. American Heart Journal, 2016, 175, 160-167.	1.2	8

#	Article	IF	CITATIONS
163	Clinical outcomes of percutaneous coronary intervention in patients turned down for surgical revascularization. Catheterization and Cardiovascular Interventions, 2017, 90, 94-101.	0.7	8
164	Radial Access Use for Percutaneous Coronary Intervention in Dialysis Patients. Circulation: Cardiovascular Interventions, 2020, 13, e008418.	1.4	8
165	Hospital and Operator Variation in Cardiac Rehabilitation Referral and Participation After Percutaneous Coronary Intervention: Insights From Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008242.	0.9	8
166	Impact of Worsening Renal Dysfunction on the Comparative Efficacy of Bivalirudin and Platelet Glycoprotein Ilb/Illa Inhibitors. Circulation: Cardiovascular Interventions, 2013, 6, 688-693.	1.4	7
167	The double jeopardy of chronic obstructive pulmonary disease and myocardial infarction. Open Heart, 2014, 1, e000010.	0.9	7
168	Middle-of-the-Night Percutaneous Coronary Intervention and its Association With Percutaneous Coronary Intervention Outcomes Performed the Following Day. JACC: Cardiovascular Interventions, 2015, 8, 49-56.	1.1	7
169	Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy—a propensity-adjusted analysis. American Heart Journal, 2006, 151, 1031.e1-1031.e6.	1.2	6
170	Predicting Contrast-induced Renal Complications in the Catheterization Laboratory. Interventional Cardiology Clinics, 2014, 3, 369-377.	0.2	6
171	Use of a Heart Team in Decision-Making for Patients with Complex Coronary Disease at Hospitals in Michigan Prior to Guideline Endorsement. PLoS ONE, 2014, 9, e113241.	1.1	6
172	Non-invasive thrombolysis induced by histotripsy pulsed cavitation ultrasound therapy. , 2008, , .		5
173	Predicting complications of percutaneous coronary intervention using a novel support vector method. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 778-786.	2.2	5
174	Preprocedural statin use in patients undergoing percutaneous coronary intervention. American Heart Journal, 2014, 168, 110-116.e3.	1.2	5
175	Primary percutaneous coronary intervention at centers with and without on-site surgical support: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). American Heart Journal, 2018, 195, 99-107.	1.2	5
176	The Role of Clopidogrel in Revascularized and Nonrevascularized Patients with Acute Coronary Syndromes. American Journal of Cardiovascular Drugs, 2007, 7, 159-168.	1.0	4
177	Channelling regional registries for optimization of cardiac care: lessons from around the world. European Heart Journal, 2013, 34, 83-85.	1.0	4
178	P2Y12 Inhibitors in Patients With ChronicÂKidney Disease. JACC: Cardiovascular Interventions, 2017, 10, 2026-2028.	1.1	4
179	Exploring the Healthcare Value of Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004328.	0.9	4
180	Pre-hospital Transport Times and Outcomes After Different Reperfusion Strategies for ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2019, 123, 375-381.	0.7	4

#	Article	IF	CITATIONS
181	Effects of an Electronic Medical Record Intervention on Appropriateness of Transthoracic Echocardiograms: A Prospective Study. Journal of the American Society of Echocardiography, 2021, 34, 176-184.	1.2	4
182	Novel preclinical method for evaluating the efficacy of a percutaneous treatment in human ex vivo calcified plaque. Medical and Biological Engineering and Computing, 2021, 59, 799-811.	1.6	4
183	The Association of Peri-Procedural Blood Transfusion with Morbidity and Mortality in Patients Undergoing Percutaneous Lower Extremity Vascular Interventions: Insights from BMC2 VIC. PLoS ONE, 2016, 11, e0165796.	1.1	4
184	Use of Anticoagulants in ST-Segment Elevation Myocardial Infarction Patients; A Focus on Low-Molecular-Weight Heparin. Cardiovascular Drugs and Therapy, 2008, 22, 59-69.	1.3	3
185	Carotid Artery Stenting Versus Carotid Endarterectomy: Post CREST. Current Cardiology Reports, 2012, 14, 135-141.	1.3	3
186	When Is it Right to Be Wrong?. Journal of the American College of Cardiology, 2014, 63, 427-429.	1.2	3
187	Association Of Bleeding Avoidance Strategies with age-related bleeding and In-hospital mortality in patients undergoing percutaneous coronary Interventions. Cardiovascular Revascularization Medicine, 2016, 17, 233-240.	0.3	3
188	Trends and outcomes of non-primary PCI at sites without cardiac surgery on-site: The early Michigan experience. PLoS ONE, 2020, 15, e0238048.	1.1	3
189	Marijuana Use and In-Hospital Outcomes After Percutaneous Coronary Intervention in Michigan, United States. JACC: Cardiovascular Interventions, 2021, 14, 1757-1767.	1.1	3
190	The safety of a bivalirudin-based approach in patients undergoing rotational atherectomy. Journal of Invasive Cardiology, 2007, 19, 225-8.	0.4	3
191	GP IIb/IIIa inhibitors during primary percutaneous coronary intervention for STEMI: New trial and registry data. Current Cardiology Reports, 2008, 10, 424-430.	1.3	2
192	Predicting emergency coronary artery bypass graft following PCI: application of a computational model to refer patients to hospitals with and without onsite surgical backup. Open Heart, 2015, 2, e000243.	0.9	2
193	Hydration and contrast-induced kidney injury. Lancet, The, 2017, 390, 452-453.	6.3	2
194	Effect of Location on Treatment and Outcomes of Cardiac Arrest Complicating Acute Myocardial Infarction in England & Wales. American Journal of Cardiology, 2021, 152, 1-10.	0.7	2
195	Will Urinary Dickkopf-3 Disrupt the Field of Contrast-Induced Acute KidneyÂlnjury?. Journal of the American College of Cardiology, 2021, 77, 2677-2679.	1.2	2
196	Using Propensity Score Matching in Clinical Investigations: A Discussion and Illustration. International Journal of Statistics in Medical Research, 2015, 4, 208-216.	0.5	2
197	Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Journal of Invasive Cardiology, 2017, 29, 340-351.	0.4	2
198	Defining the optimal dose of aspirin and clopidogrel in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2011, 12, 149-151.	0.9	1

#	Article	IF	CITATIONS
199	Response to Letters Regarding Article, "Risk of Acute Kidney Injury After Percutaneous Coronary Interventions Using Radial Versus Femoral Vascular Access: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium― Circulation: Cardiovascular Interventions, 2014, 7, 421-421.	1.4	1
200	Renal Complications in the Catheterization Laboratory. Interventional Cardiology Clinics, 2014, 3, xiii-xiv.	0.2	1
201	Reply. Journal of the American College of Cardiology, 2015, 66, 2574-2575.	1.2	1
202	A data driven approach for optimizing cardiac care: Acute coronary syndromes and beyond. Indian Heart Journal, 2016, 68, 114-117.	0.2	1
203	The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium. Catheterization and Cardiovascular Interventions, 2017, 90, 724-732.	0.7	1
204	The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Journal of Interventional Cardiology, 2017, 30, 291-300.	0.5	1
205	Upstream Impact of Public Reporting. Circulation: Cardiovascular Interventions, 2019, 12, e007878.	1.4	1
206	A Complementary Approach for Preventing Contrast-Induced Acute Kidney Injury. JACC: Cardiovascular Interventions, 2020, 13, 843-845.	1.1	1
207	Comparative Safety of Bioabsorbable Polymer Everolimus-Eluting, Durable Polymer Everolimus-Eluting, and Durable Polymer Zotarolimus-Eluting Stents in Contemporary Clinical Practice. Circulation: Cardiovascular Interventions, 2021, 14, e009850.	1.4	1
208	The <scp>DISCO</scp> studyâ€"Does Interventionalists' Sex impact Coronary Outcomes?. Catheterization and Cardiovascular Interventions, 2021, 98, E531-E539.	0.7	1
209	Drilling Down to Quality. JACC: Cardiovascular Interventions, 2021, 14, 1431-1433.	1.1	1
210	Percutaneous Coronary Intervention in Patients With a History of Gastrointestinal Bleeding (From) Tj ETQq0 0 C 2021, 155, 9-15.	o.7	erlock 10 Tf 50 1
211	Trends in interventional stroke device utilization during the COVID-19 pandemic. Clinical Neurology and Neurosurgery, 2021, 209, 106931.	0.6	1
212	Resistance to Antiplatelet Drugs. , 2010, , 449-464.		1
213	Abstract 16151: Acute Kidney Injury is a Powerful and an Independent Determinant of In-Hospital Mortality in Patients Undergoing Percutaneous Coronary Interventions. Circulation, 2014, 130, .	1.6	1
214	Drug-eluting versus bare metal stents-a one horse race?. Journal of Invasive Cardiology, 2010, 22, 33-4.	0.4	1
215	Case Report: The Effect of Proton Pump Inhibitor Administration on Hemodynamics in a Cardiac Intensive Care Unit. Clinical Cardiology, 2010, 33, E111-E113.	0.7	0
216	The effect of acoustic parameters on the Non-Invasive Embolus Trap (NET) using a histotripsy-generated bubble cloud. , $2011,$ ,.		0

#	Article	IF	CITATIONS
217	Drug-Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Intervention. Interventional Cardiology Clinics, 2013, 2, 283-305.	0.2	O
218	A Practical Approach to Preventing Renal Complications in the Catheterization Laboratory. Interventional Cardiology Clinics, 2014, 3, 429-439.	0.2	0
219	Reply to: Prepercutaneous coronary interventions statin therapy: Is it necessary?. American Heart Journal, 2014, 168, e13.	1.2	0
220	A digital tool for incorporating right atrial pressure into fractional flow reserve determination. Catheterization and Cardiovascular Interventions, 2018, 92, E204-E205.	0.7	0
221	Left Main Stenting. JACC: Cardiovascular Interventions, 2018, 11, 2492-2494.	1.1	0
222	Reply. JACC: Cardiovascular Interventions, 2019, 12, 2327.	1.1	0
223	Renal Disease and Coronary, Peripheral and Structural Interventions. Interventional Cardiology Clinics, 2020, 9, xi-xii.	0.2	0
224	A Practical Approach to Preventing Renal Complications in the Catheterization Laboratory. Interventional Cardiology Clinics, 2020, 9, 403-407.	0.2	0
225	Surviving the "After-Shock― JACC: Cardiovascular Interventions, 2020, 13, 1220-1222.	1.1	0
226	In-hospital death among patients undergoing percutaneous coronary intervention: A root-cause analysis. Cardiovascular Revascularization Medicine, 2022, , .	0.3	0
227	Title is missing!. , 2020, 15, e0238048.		0
228	Title is missing!. , 2020, 15, e0238048.		0
229	Title is missing!. , 2020, 15, e0238048.		0
230	Title is missing!. , 2020, 15, e0238048.		0
231	Renal Function–Based Contrast Threshold Predicts Kidney Injury in Transcatheter Aortic Valve Replacement. , 2022, 1, 100038.		O